In 2 randomized, double-blind, double-dummy trials, 339 patients were treated with topical BACTROBAN CREAM (mupirocin calcium cream) plus oral placebo. Adverse events thought to be possibly or probably drug-related occurred in 28 (8.3%) patients. The incidence of those events that were reported in at least 1% of patients enrolled in these trials were: Headache (1.7%), rash, and nausea (1.1% each).

Other adverse events thought to be possibly or probably drug-related which occurred in less than 1% of patients were: Abdominal pain, burning at application site, cellulitis, dermatitis, dizziness, pruritus, secondary wound infection, and ulcerative stomatitis.

In a supportive study in the treatment of secondarily infected eczema, 82 patients were treated with BACTROBAN CREAM (mupirocin calcium cream) . The incidence of adverse events thought to be possibly or probably drug-related was as follows: Nausea (4.9%), headache, and burning at application site (3.6% each), pruritus (2.4%) and 1 report each of abdominal pain, bleeding secondary to eczema, pain secondary to eczema, hives, dry skin, and rash.

Read the Bactroban Cream (mupirocin calcium cream) Side Effects Center for a complete guide to possible side effects »

The effect of the concurrent application of topical mupirocin calcium cream and other topical products has not been studied.

Last reviewed on RxList: 4/28/2009
This monograph has been modified to include the generic and brand name in many instances.